

Elizabeth C Martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6696834/publications.pdf>

Version: 2024-02-01

27
papers

476
citations

759233

12
h-index

713466

21
g-index

27
all docs

27
docs citations

27
times ranked

822
citing authors

#	ARTICLE	IF	CITATIONS
1	Adipose-Derived Stromal/Stem Cell Response to Tumors and Wounds: Evaluation of Patient Age. <i>Stem Cells and Development</i> , 2022, 31, 579-592.	2.1	4
2	Breast Cancer-Stromal Interactions: Adipose-Derived Stromal/Stem Cell Age and Cancer Subtype Mediated Remodeling. <i>Stem Cells and Development</i> , 2022, 31, 604-620.	2.1	3
3	Quantifying Breast Cancer-Driven Fiber Alignment and Collagen Deposition in Primary Human Breast Tissue. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 618448.	4.1	7
4	Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells. <i>Oncology Letters</i> , 2021, 21, 380.	1.8	1
5	microRNA Sequencing of CD34+ Sorted Adipose Stem Cells Undergoing Endotheliogenesis. <i>Stem Cells and Development</i> , 2021, 30, 265-288.	2.1	4
6	Breast Cancer Reconstruction: Design Criteria for a Humanized Microphysiological System. <i>Tissue Engineering - Part A</i> , 2021, 27, 479-488.	3.1	2
7	Evaluation of Extracellular Matrix Composition to Improve Breast Cancer Modeling. <i>Tissue Engineering - Part A</i> , 2021, 27, 500-511.	3.1	11
8	Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	2
9	A Role for Adipocytes and Adipose Stem Cells in the Breast Tumor Microenvironment and Regenerative Medicine. <i>Frontiers in Physiology</i> , 2021, 12, 751239.	2.8	15
10	Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor. <i>PLoS ONE</i> , 2020, 15, e0226464.	2.5	13
11	ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1164.	2.8	13
12	Proteomic characterization of a trauma-based rat model of heterotopic ossification identifies interactive signaling networks as potential therapeutic targets. <i>Journal of Proteomics</i> , 2020, 226, 103907.	2.4	1
13	Patient-Derived Xenografts as an Innovative Surrogate Tumor Model for the Investigation of Health Disparities in Triple Negative Breast Cancer. <i>Women S Health Reports</i> , 2020, 1, 383-392.	0.8	4
14	Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line. <i>Nanomedicine</i> , 2020, 15, 981-1000.	3.3	19
15	Acellular Biologic Nipple-Areolar Complex Graft: <i>In Vivo</i> Murine and Nonhuman Primate Host Response Evaluation. <i>Tissue Engineering - Part A</i> , 2020, 26, 872-885.	3.1	5
16	Transcriptomic Profiling of Adipose Derived Stem Cells Undergoing Osteogenesis by RNA-Seq. <i>Scientific Reports</i> , 2019, 9, 11800.	3.3	31
17	Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model. <i>BMC Cancer</i> , 2019, 19, 205.	2.6	19
18	Comparative proteomic analyses of human adipose extracellular matrices decellularized using alternative procedures. <i>Journal of Biomedical Materials Research - Part A</i> , 2018, 106, 2481-2493.	4.0	37

#	ARTICLE	IF	CITATIONS
19	A novel patient-derived xenograft model for claudin-low triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 381-390.	2.5	19
20	Trauma induced heterotopic ossification patient serum alters mitogen activated protein kinase signaling in adipose stem cells. <i>Journal of Cellular Physiology</i> , 2018, 233, 7035-7044.	4.1	12
21	Engineering Breast Cancer Microenvironments and 3D Bioprinting. <i>Frontiers in Bioengineering and Biotechnology</i> , 2018, 6, 66.	4.1	77
22	Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model. <i>Oncoscience</i> , 2018, 5, 99-108.	2.2	15
23	MicroRNA-335-5p and -33p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. <i>FEBS Letters</i> , 2017, 591, 382-392.	2.8	52
24	Endocrine disruptors and the tumor microenvironment: A new paradigm in breast cancer biology. <i>Molecular and Cellular Endocrinology</i> , 2017, 457, 13-19.	3.2	35
25	Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation. <i>Non-coding RNA</i> , 2016, 2, 8.	2.6	11
26	Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. <i>International Journal of Oncology</i> , 2013, 42, 1139-1150.	3.3	32
27	Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance. <i>Scientific Reports</i> , 2012, 2, 539.	3.3	32